Universe Financial Statements From 2010 to 2025

UPC Stock  USD 3.65  0.37  9.20%   
Universe Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Universe Pharmaceuticals' valuation are provided below:
Gross Profit
5.9 M
Profit Margin
(0.50)
Market Capitalization
2.3 M
Enterprise Value Revenue
0.0174
Revenue
19.3 M
We have found one hundred twenty available fundamental trend indicators for Universe Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Universe Pharmaceuticals' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Universe Pharmaceuticals Total Revenue

26.96 Million

Check Universe Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Universe Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 518.7 K, Depreciation And Amortization of 508 K or Interest Expense of 175.5 K, as well as many indicators such as Price To Sales Ratio of 0.0422, Dividend Yield of 0.0765 or PTB Ratio of 0.0214. Universe financial statements analysis is a perfect complement when working with Universe Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Universe Stock
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

Universe Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets51.2 M78.1 M40.7 M
Slightly volatile
Short and Long Term Debt Total3.9 M6.3 M3.5 M
Slightly volatile
Other Current LiabilitiesM2.9 M6.8 M
Slightly volatile
Total Current Liabilities14.2 M23.4 M16 M
Pretty Stable
Total Stockholder Equity36.7 M52.3 M24.4 M
Slightly volatile
Net Tangible Assets32.4 M53.2 M24.5 M
Slightly volatile
Property Plant And Equipment Net11.5 M17.6 M8.6 M
Slightly volatile
Current Deferred Revenue714.8 K804.2 K876.8 K
Slightly volatile
Accounts PayableM5.7 M3.5 M
Slightly volatile
Cash35.6 M33.9 M11.3 M
Slightly volatile
Non Current Assets Total13.8 M18.8 M10.2 M
Slightly volatile
Other Assets15.6 M14.9 M5.3 M
Slightly volatile
Cash And Short Term Investments14.4 M21.3 M11 M
Slightly volatile
Net Receivables12.8 M14.8 M10.2 M
Slightly volatile
Common Stock Total Equity40 K45 K49.1 K
Slightly volatile
Common Stock Shares Outstanding47.6 K45.3 K13 K
Slightly volatile
Liabilities And Stockholders Equity47.2 M61.3 M38.5 M
Slightly volatile
Inventory2.6 M1.6 M5.2 M
Slightly volatile
Other Current Assets931.3 K980.3 K1.3 M
Slightly volatile
Other Stockholder Equity18.1 M33.7 M12.9 M
Slightly volatile
Total Liabilities14.5 M25.8 M16.3 M
Very volatile
Net Invested Capital41.3 M61.5 M28.2 M
Slightly volatile
Long Term Investments572.5 K641.2 K707.4 K
Slightly volatile
Property Plant And Equipment Gross14.4 M25.3 M10.4 M
Slightly volatile
Short and Long Term Debt4.3 M6.7 M3.5 M
Slightly volatile
Total Current Assets37.3 M59.4 M30.5 M
Slightly volatile
Accumulated Other Comprehensive Income22.5 K23.6 K2.3 M
Slightly volatile
Capital Stock582.5 K554.8 K145.2 K
Slightly volatile
Net Working Capital23.2 M36 M14.5 M
Slightly volatile
Short Term Debt3.9 M6.3 M3.5 M
Slightly volatile
Intangible Assets200.7 K302.3 K191.6 K
Slightly volatile
Common Stock64.9 K78.2 K57.2 K
Slightly volatile
Property Plant Equipment3.7 M3.8 M4.7 M
Slightly volatile
Non Currrent Assets Other30.7 K32.3 K1.9 M
Slightly volatile
Long Term Debt1.7 M1.9 M2.1 M
Slightly volatile

Universe Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision518.7 K546 K1.7 M
Slightly volatile
Depreciation And Amortization508 K585.1 K471.4 K
Slightly volatile
Interest Expense175.5 K319.9 K172.9 K
Slightly volatile
Selling General Administrative12.6 M12 M3.2 M
Slightly volatile
Selling And Marketing ExpensesM7.8 M4.1 M
Slightly volatile
Total Revenue27 M20.7 M30.2 M
Very volatile
Gross Profit5.2 M5.5 M13.1 M
Slightly volatile
Other Operating Expenses33.1 M41.7 M26.5 M
Slightly volatile
Research Development3.6 M3.5 M2.2 M
Slightly volatile
Cost Of Revenue20.6 M19.5 M17.3 M
Slightly volatile
Total Operating Expenses37.5 M35.7 M12.2 M
Slightly volatile
Reconciled Depreciation511.8 K558.6 K468.5 K
Slightly volatile
Income Tax Expense1.6 MMM
Very volatile

Universe Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.2 M4.8 M6.5 M
Slightly volatile
Depreciation511.8 K558.6 K468.5 K
Slightly volatile
Capital Expenditures396.7 K417.6 KM
Pretty Stable
End Period Cash Flow35.6 M33.9 M11.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.04220.04442.2339
Slightly volatile
Dividend Yield0.07650.140.089
Slightly volatile
PTB Ratio0.02140.02256.0295
Slightly volatile
Days Sales Outstanding268255137
Slightly volatile
Book Value Per Share4.6 K6.7 KK
Slightly volatile
Average Payables3.5 M4.3 M4.1 M
Pretty Stable
Capex To Depreciation0.640.672.2185
Pretty Stable
PB Ratio0.02140.02256.0295
Slightly volatile
Inventory Turnover5.948.784.9815
Slightly volatile
Days Of Inventory On Hand72.7543.01122
Slightly volatile
Payables Turnover6.283.975.3893
Very volatile
Sales General And Administrative To Revenue0.130.120.053
Slightly volatile
Average Inventory4.2 M2.6 M4.2 M
Slightly volatile
Research And Ddevelopement To Revenue0.07440.120.065
Slightly volatile
Capex To Revenue0.01350.01420.0234
Pretty Stable
Cash Per Share4.6 K4.4 K2.2 K
Slightly volatile
Payout Ratio1.011.911.1785
Slightly volatile
Days Payables Outstanding56.5495.2471.4717
Pretty Stable
Intangibles To Total Assets0.00540.00440.0056
Slightly volatile
Current Ratio2.192.292.0009
Slightly volatile
Tangible Book Value Per Share4.6 K6.7 K3.9 K
Slightly volatile
Receivables Turnover1.411.483.1441
Slightly volatile
Shareholders Equity Per Share4.6 K6.7 KK
Slightly volatile
Debt To Equity0.170.20.2087
Slightly volatile
Capex Per Share51.0853.77186
Pretty Stable
Average Receivables5.6 M6.3 M6.9 M
Slightly volatile
Revenue Per Share6.4 K4.4 K5.4 K
Pretty Stable
Interest Debt Per Share1.3 K1.2 K694
Slightly volatile
Debt To Assets0.110.140.0986
Slightly volatile
Graham Number22 K20.9 K13.1 K
Slightly volatile
Operating Cycle165289247
Slightly volatile
Price Book Value Ratio0.02140.02256.0295
Slightly volatile
Days Of Payables Outstanding56.5495.2471.4717
Pretty Stable
Dividend Payout Ratio1.011.911.1785
Slightly volatile
Ebt Per Ebit0.820.910.9899
Pretty Stable
Company Equity Multiplier1.741.722.175
Slightly volatile
Long Term Debt To Capitalization0.03590.04040.044
Slightly volatile
Total Debt To Capitalization0.140.170.1696
Slightly volatile
Debt Equity Ratio0.170.20.2087
Slightly volatile
Quick Ratio1.982.211.6725
Slightly volatile
Net Income Per E B T0.790.970.8924
Slightly volatile
Cash Ratio1.371.310.6378
Slightly volatile
Cash Conversion Cycle108193176
Slightly volatile
Days Of Inventory Outstanding72.7543.01122
Slightly volatile
Days Of Sales Outstanding268255137
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.550.931.4285
Pretty Stable
Price To Book Ratio0.02140.02256.0295
Slightly volatile
Fixed Asset Turnover1.641.734.5158
Slightly volatile
Debt Ratio0.110.140.0986
Slightly volatile
Price Sales Ratio0.04220.04442.2339
Slightly volatile
Asset Turnover0.370.390.8823
Slightly volatile
Gross Profit Margin0.470.30.4407
Slightly volatile
Price Fair Value0.02140.02256.0295
Slightly volatile

Universe Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap711.7 K800.7 K873 K
Slightly volatile

Universe Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Universe Pharmaceuticals Financial Statements

Universe Pharmaceuticals stakeholders use historical fundamental indicators, such as Universe Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Universe Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Universe Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Universe Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue804.2 K714.8 K
Total Revenue20.7 M27 M
Cost Of Revenue19.5 M20.6 M
Sales General And Administrative To Revenue 0.12  0.13 
Research And Ddevelopement To Revenue 0.12  0.07 
Capex To Revenue 0.01  0.01 
Revenue Per Share4.4 K6.4 K
Ebit Per Revenue(0.40)(0.38)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.82)
Earnings Share
(255.68)
Revenue Per Share
104.406
Quarterly Revenue Growth
(0.29)
Return On Assets
(0.08)
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.